Henan Cancer Hospital
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1977-01-01
- Employees
- -
- Market Cap
- -
Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma
Phase 2
Recruiting
- Conditions
- Primary Central Nervous System Lymphoma
- Interventions
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT04737889
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China
Continuing Cetuximab Plus Chemotherapy After First Progression in Wild-type KRAS, NRAS and BRAF V600E Metastatic Colorectal Cancer
Completed
- Conditions
- Wild-type KRAS,NRAS and BRAF V600E Metastatic Colorectal Cancer
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04718038
Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.
Phase 2
Active, not recruiting
- Conditions
- HER2 Positive Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 46
- Registration Number
- NCT04681287
- Locations
- 🇨🇳
Henan cancer hospital, Zhengzhou, Henan, China
Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer
Not Applicable
- Conditions
- Advanced Gastric Adenocarcinoma
- Interventions
- Other: Camrelizumab, Albumin-bound paclitaxel, S-1
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2022-04-15
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 46
- Registration Number
- NCT04675866
- Locations
- 🇨🇳
Henan Tumor Hospital, Ho-nan, Henan, China
Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma
Phase 2
Suspended
- Conditions
- Diffuse Large B Cell LymphomaCD79B Gene MutationCD79A Gene Mutation
- Interventions
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 59
- Registration Number
- NCT04668365
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China
Comparison of TP and TAC Regimens in Neoadjuvant Treatment of TNBC
Phase 2
Completed
- Conditions
- Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2020-12-11
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 212
- Registration Number
- NCT04664972
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
Phase 2
- Conditions
- SCLC, Extensive Stage
- Interventions
- Drug: Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT04660097
- Locations
- 🇨🇳
Henan Tumor Hospital, Zhengzhou, Henan, China
A Trail of CDK4 / 6 Inhibitor and MEK Inhibitor in the Treatment of Metastatic Digestive System Tumors
Phase 1
- Conditions
- Digestive System Tumors
- Interventions
- Drug: a CDK4 / 6 inhibitor and a MEK inhibitor
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT04615312
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer
- First Posted Date
- 2020-09-18
- Last Posted Date
- 2021-11-26
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT04553939
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Comparing the Efficacy of Nab-PHP and TCbHP in Neoadjuvant Therapy for HER2 Positive Operable Breast Cancer
Phase 3
Recruiting
- Conditions
- Breast Cancer,HER2-positive
- Interventions
- Drug: Nab-paclitaxel+ trastuzumab+ patuzumab
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 688
- Registration Number
- NCT04547907
- Locations
- 🇨🇳
Henan cancer hospital, Zhengzhou, Henan, China
© Copyright 2025. All Rights Reserved by MedPath